儿童肺结核γ-干扰素释放试验假阴性结果影响因素分析

doi:10.12372/jcp.2025.24e0168

Abstract

Abstract:

Objective To investigate the diagnostic value of interferon-gamma release assay (IGRA) in pediatric pulmonary tuberculosis (PTB) and analyze the risk factors of negative IGRA results. Method A total of 77 children with confirmed PTB who were hospitalized in our hospital from January 2018 to June 2023 were included in the study. Based on IGRA results, they were categorized into positive and false-negative groups. The sensitivity of IGRA for diagnosing pediatric PTB was evaluated, and the factors contributing to false-negative results were analyzed. Result The sensitivity of Tuberculin skin test (TST) for diagnosing pediatric PTB was 67.53% (52/77), while that of IGRA was 77.92% (60/77). The agreement rate between TST and IGRA was 79.22%, with a Kappa value of 0.48, indicating moderate consistency. Multivariate analysis revealed that the induration reaction of TST (moderate positive OR=0.066, 95%CI:0.009-0.471, P=0.007, strong positive OR=0.023, 95%CI: 0.002-0.275, P=0.003) and albumin-to-globulin ratio (OR=17.193,95%CI: 2.379-124.247, P=0.005) were independent predictors of false-negative IGRA results. Conclusion Due to the immature development of the immune system, children should be vigilant against the possibility of false negative results of IGRA. Emphasis on molecular biological and pathological examinations is crucial for achieving an early and accurate diagnosis, thereby preventing delayed treatment and missed opportunities for optimal care.

Key words: pulmonary tuberculosis, interferon-gamma release assay, false negative, child

CLC Number:

JIANG Wenwen, LI Sitong, XU Yongsheng. Analysis on risk factors associated with false-negative results of interferon-gamma release assay in children with pulmonary tuberculosis[J].Journal of Clinical Pediatrics, 2025, 43(7): 519-524.

Figures/Tables 4

Table 1

Table 2

Table 3

Table 4

References 20

[1]	WHO. World Health Organization; 2021.Licence: CC BY-NC-SA 3.0 IGO; Geneva:2021. Global tuberculosis report 2021 [EB/OL]. [2022-10-27]. https://www.who.int/publications/i/item/9789240037021.
[2]	Ho CS, Feng PI, Narita M, et al. Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study[J]. Lancet Infect Dis, 2022, 22(1): 85-96.
[3]	Jonas DE, Riley SR, Lee LC, et al. Screening for latent tuberculosis infection in adults: updated evidence report and systematic review for the US preventive services task force[J]. Jama, 2023, 329(17): 1495-1509. doi: 10.1001/jama.2023.3954 pmid: 37129650
[4]	Krutikov M, Faust L, Nikolayevskyy V, et al. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2022, 22(2): 250-264.
[5]	钟旭辉, 丁洁, 周建华, 等. 中国儿童15项常用临床检验指标的生物参考区间研究[J]中华儿科杂志, 2018, 56(11): 835-845.
	Zhong XH, Ding J, Zhou JH, et al. Biological reference interval study of 15 commonly used clinical test indexes in Chinese children[J]. Zhonghua Erke Zazhi, 2018, 56(11): 835-845.
[6]	Ding Y, Zhou L, Xia Y, et al. Reference values for peripheral blood lymphocyte subsets of healthy children in China[J]. J Allergy Clin Immunol, 2018, 142(3): 970-973. doi: S0091-6749(18)30693-6 pmid: 29746882
[7]	Carranza C, Pedraza-Sanchez S, De Oyarzabal-Mendez E, et al. Diagnosis for latent tuberculosis infection: new alternatives[J]. Front Immunol, 2020, 11: 2006. doi: 10.3389/fimmu.2020.02006 pmid: 33013856
[8]	Yang J, Kong W, Xv N, et al. Correlation between the tuberculin skin test and T-SPOT.TB in patients with suspected tuberculosis infection: a pilot study[J]. Exp Ther Med, 2019, 18(3): 2250-2254. doi: 10.3892/etm.2019.7791 pmid: 31410176
[9]	De Visser V, Sotgiu G, Lange C, et al. False-negative interferon-γ release assay results in active tuberculosis: a TBNET study[J]. Eur Respir J, 2015, 45(1): 279-283. doi: 10.1183/09031936.00120214 pmid: 25359336
[10]	Ahmed A, Vyakarnam A. Emerging patterns of regulatory T cell function in tuberculosis[J]. Clin Exp Immunol, 2020, 202(3): 273-287.
[11]	高卫卫, 邓常文, 朱晓萍. 调节性T细胞在结核免疫调控中的研究进展[J]. 临床肺科杂志, 2022, 27(8): 1238-1242.
	Gao WW, Deng CW, Zhu XP. Research progress of regulatory T cells in the regulation of tuberculosis immunity[J]. Linchuang Feike Zazhi, 2022, 27(8): 1238-1242.
[12]	Bond E, Liang F, Sandgren KJ, et al. Plasmacytoid dendritic cells infiltrate the skin in positive tuberculin skin test indurations[J]. J Invest Dermatol, 2012, 132(1): 114-123. doi: 10.1038/jid.2011.246 pmid: 21850028
[13]	Serrano CJ, Castañeda-Delgado JE, Trujillo-Ochoa JL, et al. Regulatory T-cell subsets in response to specific Mycobacterium tuberculosis antigens in vitro distinguish among individuals with different QTF and TST reactivity[J]. Clin Immunol, 2015, 157(2): 145-155. doi: 10.1016/j.clim.2015.02.008 pmid: 25728490
[14]	Gough M, Singh DK, Moodley C, et al. Peripheral blood markers correlate with the progression of active tuberculosis relative to latent control of Mycobacterium tuberculosis infection in macaques[J]. Pathogens, 2022, 11(5): 544.
[15]	Esaulova E, Das S, Singh DK, et al. The immune landscape in tuberculosis reveals populations linked to disease and latency[J]. Cell Host Microbe, 2021, 29(2): 165-178. doi: 10.1016/j.chom.2020.11.013 pmid: 33340449
[16]	Turner NA, Ahmed A, Haley CA, et al. Use of interferon-gamma release assays in children < 2 years old[J]. J Pediatric Infect Dis Soc, 2023, 12(8): 481-485.
[17]	马进宝, 马婷婷, 任斐, 等. 涂阳肺结核患者γ-干扰素释放试验假阴性的影响因素分析[J]. 中国防痨杂志, 2020, 42(12): 1299-1304.
	Ma JB, Ma TT, Ren F, et al. Analysis on risk factors associated with false negative results of interferon-gamma release assay in active tuberculosis[J]. Zhongguo Fanglao Zazhi, 2020, 42(12): 1299-1304.
[18]	彭涛, 如克亚木·阿不都沙拉木, 房珂, 等. 活动性肺结核免疫耗竭及免疫治疗的研究进展[J]. 传染病信息, 2022, 35(1): 90-94.
	Peng T, Ru Ke Ya Mu·ABDSLM, Fang K, et al. Research progress on immune exhaustion and immunotherapy of active pulmonary tuberculosis[J]. Chuanranbing Xinxi, 2022, 35(1): 90-94.
[19]	王丽, 熊坤龙, 朱长太, 等. T淋巴细胞耗竭在耐多药肺结核患者免疫表达中的初步研究[J]. 中国防痨杂志, 2021, 43(8): 808-812.
	Wang L, Xiong KL, Zhu CT, et al. T lymphocyte exhaustion on the expression of immune effect in patients with multidrug-resistant pulmonary tuberculosis[J]. Zhongguo Fanglao Zazhi, 2021, 43(8): 808-812.
[20]	刘珍敏, 赵瑞秋, 许红梅. 结核感染T细胞斑点试验、涂片检查和结核菌素试验在儿童结核病诊断中的价值[J]. 临床儿科杂志, 2019, 37(4): 282.
	Liu ZM, Zhao RQ, Xu HM. Comparison of T-cell spot test, smear test, and tuberculin test in the diagnosis of tuberculosis in children[J]. Linchuang Erke Zazhi, 2019, 37(4): 282.

项目	阳性组(n=60)	阴性组(n=17)	统计量	P
性别（男/女）	28/32	8/9	0.00	0.977
年龄[M(P₂₅~P₇₅]/岁	12.04(9.04~13.83)	3.92(0.54~7.92)	3.19	0.001
<1	4(6.67)	5(29.41)	16.18	0.003
1~<3	3(5.00)	2(11.76)
3~<7	4(6.67)	3(17.65)
7~<10	7(11.67)	4(23.53)
10~<18	42(70.00)	3(17.65)
BMI[M(P₂₅~P₇₅)]/kg·m^-2	16.00(14.76~18.16)	15.42(14.27~16.82)	1.28	0.199
BCG接种史[n(%)]	58(96.67)	16(94.12)	-	0.532¹⁾
结核接触史[n(%)]	26(43.33)	4(23.53)	2.19	0.139
居住地（农村/城市）	49/11	16/1	0.76	0.384
肺外结核[n(%)]	7(11.67)	5(29.41)	1.97	0.161
下呼吸道感染[n(%)]	13(21.67)	9(52.94)	4.91	0.027
发热[n(%)]	38(63.33)	11(64.71)	0.01	0.917
咳嗽咳痰≥2周[n(%)]	51(85.00)	10(58.82)	4.04	0.044
体重减轻[n(%)]	13(21.67)	2(11.76)	0.32	0.573
胸痛[n(%)]	8(13.33)	1(5.88)	0.17	0.667
咯血或痰中带血[n(%)]	6(10.00)	1(5.88)	0.00	0.965

项目	阳性组(n=60)	阴性组(n=17)	统计量	P
TST硬结反应[n(%)]			χ²=19.27	<0.001
阴性	9(15.00)	12(70.59)
一般阳性	3(5.00)	1(5.88)
中度阳性	23(38.33)	3(17.65)
强阳性	25(41.67)	1(5.88)
HGB（ x±s）/g·L^-1	122.33±12.70	110.82±17.38	t=3.03	0.003
WBC×10⁹[M(P₂₅~P₇₅)]/L^-1	7.98(6.71~9.75)	10.07(6.83~13.51)	Z=1.84	0.066
N×10⁹[M(P₂₅~P₇₅)]/L^-1	5.02(3.67~6.75)	4.84(2.57~9.15)	Z=0.20	0.839
L×10⁹[M(P₂₅~P₇₅)]/L^-1	1.81(1.47~2.40)	2.84(1.79~4.12)	Z=2.29	0.022
M×10⁹[M(P₂₅~P₇₅)]/L^-1	0.66(0.44~0.92)	0.67(0.53~0.86)	Z=0.31	0.759
E×10⁹[M(P₂₅~P₇₅)]/L^-1	0.09(0.03~0.15)	0.11(0.03~0.28)	Z=0.82	0.410
PLT×10⁹[M(P₂₅~P₇₅)]/L^-1	364.38±86.25	363.94±166.14	t=0.01	0.992
CPR[M(P₂₅~P₇₅)]/mg·L^-1	16.50(3.10~40.65)	7.00(2.50~73.31)	Z=0.28	0.776
NLR[M(P₂₅~P₇₅)]	2.54(1.58~4.54)	1.54(0.84~4.77)	Z=1.52	0.128
LMR[M(P₂₅~P₇₅)]	3.15(1.90~4.57)	4.06(2.60~7.39)	Z=1.82	0.069
PLR[M(P₂₅~P₇₅)]	197.14(133.21~251.71)	104.42(80.07~186.90)	Z=2.49	0.013

项目	阳性组(n=60)	阴性组(n=17)	统计量	P
LDH[M(P₂₅~P₇₅)]/U·L^-1	259.00(211.25~340.00)	305.00(230.50~367.00)	Z=1.17	0.243
PCT[M(P₂₅~P₇₅)]/ng·mL^-1	0.06(0.04~0.12)	0.05(0.04~0.21)	Z=0.51	0.613
IL-6[M(P₂₅~P₇₅)]/pg·mL^-1	17.87(7.00~34.14)	23.98(1.73~50.11)	Z=0.26	0.792
ALB[M(P₂₅~P₇₅)]/g·L^-1	42.30(39.93~45.10)	40.80(36.60~44.55)	Z=1.01	0.314
GLB[M(P₂₅~P₇₅)]/g·L^-1	29.10(25.18~31.48)	23.70(17.95~27.55)	Z=3.04	0.002
A/G（ x±s）	1.49±0.34	1.85±0.62	t=2.31	0.033
IgG相对率[M(P₂₅~P₇₅)]	1.08(0.89~1.19)	1.08(0.89~1.16)	Z=0.20	0.844
IgA相对率[M(P₂₅~P₇₅)]	1.27(0.83~1.72)	1.14(0.93~1.81)	Z=0.21	0.835
IgM相对率[M(P₂₅~P₇₅)]	0.87(0.65~1.09)	0.85(0.50~1.65)	Z=0.03	0.976
IgE[M(P₂₅~P₇₅)]/IU·mL^-1	91.92(23.49~250.03)	65.14(16.03~543.60)	Z=0.18	0.854
CD3⁺相对率[M(P₂₅~P₇₅)]	0.75(0.60~1.12)	0.93(0.54~1.38)	Z=0.98	0.326
CD4⁺相对率（ x±s）	0.95±0.43	1.09±0.71	t=0.76	0.459
CD8⁺相对率[M(P₂₅~P₇₅)]	0.76(0.51~1.02)	0.91(0.54~1.38)	Z=1.05	0.294
CD4⁺/CD8⁺[M(P₂₅~P₇₅)]	1.54(1.22~1.98)	1.48(1.12~2.41)	Z=0.50	0.619

变量/指标	β	SE	χ²值	df	P	OR	95%CI
TST硬结反应			12.32	3	0.006
一般阳性	2.63	1.74	2.30	1	0.129	0.07	0.002~2.159
中度阳性	2.72	1.00	7.34	1	0.007	0.07	0.009~0.471
强阳性	3.77	1.26	8.89	1	0.003	0.02	0.002~0.275
HGB	0.05	0.03	3.49	1	0.062	0.95	0.901~1.003
A/G	2.85	1.01	7.95	1	0.005	17.19	2.379~124.247

Analysis on risk factors associated with false-negative results of interferon-gamma release assay in children with pulmonary tuberculosis

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 20

Related Articles 15

Metrics

Comments

Recommended 0

[1]	Chinese Cooperative Group for the Management of Pediatric Enuresis Affiliated to Pediatric Nephrology Committee of Chinese Medical Doctor Association. Chinese expert consensus on management of nocturnal enuresis in children [J]. Journal of Clinical Pediatrics, 2025, 43(7): 483-499.
[2]	WANG Yingshuo, CHEN Zhimin. Leveraging digital intelligence to enhance the diagnosis, treatment, and management of pediatric bronchial asthma [J]. Journal of Clinical Pediatrics, 2025, 43(7): 500-504.
[3]	ZHAO Linchao, WANG Yingjie, JING Zhaohe, MAI Yumiao, SUN Pan, QIU Simin, NIU Hongyun, CHEN Zhiwei, DONG Pengpeng, LIU Jian. Analysis of the efficacy and prognosis of hematopoietic stem cell transplantation for inherited bone marrow failure syndrome in children [J]. Journal of Clinical Pediatrics, 2025, 43(7): 505-510.
[4]	ZHANG Zhiqi, XIONG Ruolan, LI Bohan, JI Qi, WANG Qingwei, LU Jun, LI Jie, XIAO Peifang, HU Shaoyan. Construction of risk prediction model for primary graft failure after umbilical cord blood transplantation in pediatric leukemia [J]. Journal of Clinical Pediatrics, 2025, 43(7): 511-518.
[5]	LI Fan, HUANG Xianjie, FAN Yazhen, ZHAO Jianchuang, CUI Chenhang, GUO Qiliang, QIAO Junying. Tocilizumab treatment for febrile infection-related epilepsy syndrome in children: 2 cases report and literature review [J]. Journal of Clinical Pediatrics, 2025, 43(7): 532-538.
[6]	DUAN Haolin, ZHANG Ciliu, XIONG Juan, PANG Nan, YIN Fei, PENG Jing. Clinical efficacy analysis of disease-modifying therapies for spinal muscular atrophy with SMN1 gene compound heterozygous variants [J]. Journal of Clinical Pediatrics, 2025, 43(7): 543-548.
[7]	HE Shuang, XU Xin, ZHOU Xue, LIU Qian, ZHANG Lei, TIAN Jie, LYU Tiewei. Leadless cardiac pacemaker implantation via the internal jugular vein: clinical practice and reflection of a 15kg child with third-degree atrioventricular block after congenital heart surgery [J]. Journal of Clinical Pediatrics, 2025, 43(7): 549-553.
[8]	LI Fen. Promoting the research and application of leadless cardiac pacemakers in children [J]. Journal of Clinical Pediatrics, 2025, 43(7): 554-555.
[9]	LYU Mingjun, LUO Wen, YANG Jinxiang, LIANG Jianying, YAO Zhirong. Progress in pathogenesis and treatment of pediatric generalized pustular psoriasis [J]. Journal of Clinical Pediatrics, 2025, 43(7): 556-562.
[10]	ZHANG Hongwen. Application and consideration of eculizumab in the treatment of childhood systemic lupus erythematosus [J]. Journal of Clinical Pediatrics, 2025, 43(6): 403-407.
[11]	LI Qiuyu, LIU Fei, ZHAO Manli, GU Weizhong, FENG Chunyue, FU Haidong. Clinicopathological analysis of 3496 pediatric patients with renal disease: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2025, 43(6): 411-417.
[12]	WANG Ruixue, WANG Runjie, LI Xiaolu, ZHANG Ting, XIAO Yongmei. Analysis of clinical characteristics, endoscopic and pathological manifestations of children with positive lactulose hydrogen-methane breath test [J]. Journal of Clinical Pediatrics, 2025, 43(6): 418-425.
[13]	YUE Yang, ZHANG Zhihua, LI Mei, LIU Zhifeng, GUO Hongmei. Predictors of efficacy of infliximab induction therapy in children with Crohn's disease [J]. Journal of Clinical Pediatrics, 2025, 43(6): 426-431.
[14]	XIE Lilin, XU Jinping, YAO Yonghua. Pediatric arterial ischemic stroke: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2025, 43(6): 432-437.
[15]	DU Tingting, YAO Hui, CHEN Xiaohong, YANG Luhong, FENG Lifang, CHEN Xiaoqian, HU Man, LI Yakun. A study examining the association between hypopituitarism and metabolic-associated fatty liver disease following surgery for tumors in the sellar region among children [J]. Journal of Clinical Pediatrics, 2025, 43(6): 438-444.